Protein Kinase Inhibitors: Synthesis and Applications
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Chemical Biology".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 5339
Special Issue Editors
Interests: inhibitor; neoplasms; immune system; degenerative diseases
Special Issue Information
Dear Colleagues,
The abnormality of protein kinase activity is involved in the pathogenesis of all kinds of diseases including cancer, inflammatory, cardiovascular, nervous and degenerative diseases, and have become one of the most important drug targets in the 21st century. Especially receptor tyrosine kinase signaling pathways have been essential targets in cancer therapy. Up to now, 89 protein kinase inhibitors have been approved and several hundreds have been used in the clinics. However, protein kinases remain to be discovered as targets for new biological processes and disease areas leading to the development and application of novel protein kinase inhibitors. Recently, ideas for the improvement of the kinome-wide selectivity of protein kinase inhibitors included covalent synthetic strategies and prolongation of the binding kinetics of the inhibitor-protein kinase complex. Selective so-called chemogenomic protein kinase inhibitors can be used as tool compounds to identify their targets in phenotypic assay systems.
This Special Issue provides a broad survey to release your most recent work on synthesis and applications, new strategies and technologies on the generation or evaluation of protein kinase inhibitors in different disease areas. Original research articles or reviews aiming at the development and applications of protein kinase inhibitors in different fields are welcome.
Dr. Cheng Wang
Dr. Benedict-Tilman Berger
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inhibitor
- neoplasms
- immune system
- degenerative diseases
- covalent inhibition
- inhibitor binding kinetics
- chemogenomic kinase inhibitors
